Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
2.7
3.2
Journals
Life
Special Issues
Evolving Chemotherapies in Glioblastomas(GBM)—Present and Future
share announcement

Evolving Chemotherapies in Glioblastomas(GBM)—Present and Future

A special issue of Life (ISSN 2075-1729). This special issue belongs to the section "Medical Research".

Deadline for manuscript submissions: closed (28 July 2023) | Viewed by 2856

Special Issue Editors

Dr. Crismita Dmello

E-Mail Website
Guest Editor
Department of Neurological Surgery, Northwestern University, Chicago, IL 60611, USA
Interests: tumor biology; cell biology; molecular biology
Dr. Fatima Khan

E-Mail Website
Guest Editor
Department of Neurological Surgery, Northwestern University, Chicago, IL 60611, USA
Interests: tumor immunity; cancer biology; metabolism; exosomes; immunotherapy; cell signaling; cellular mechanisms; tumor microenvironment; phage screening; protein–protein interaction; peptide; molecular epigenetics

Special Issue Information

Dear Colleagues,

Glioblastomas (GBM) have remained challenging to treat despite the innovative and revolutionary research taking place worldwide. The current standard of care for GBM, which includes surgery, radiation and chemotherapy with the blood–brain barrier (BBB)-permeable drug temozolomide (TMZ), has not been shown to be capable of extending the median survival time of GBM patients beyond 14.5 months. The response to TMZ is further dampened in O6-methylguanine-DNA methyltransferase (MGMT)-unmethylated patients. The results of various large-scale clinical trials using immune-checkpoint blockades have predicted depressing outcomes for GBM patients. An almost 100% recurrence rate, a highly immunosuppressive environment, heterogeneity and an intact BBB in the peritumoral region of the brain makes most of the therapies ineffective. Various emerging chemotherapy regimens are under development and/or in clinical trials which have shown promise in preclinical models by overcoming the unconducive GBM environment. In this Special Issue, we want to discuss all such chemotherapy-based studies that give hope to patients and to the field of GBM and are the path forward for research into GBM.

Dr. Crismita Dmello
Dr. Fatima Khan
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Life is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cancer biology
  • immunotherapy
  • glioblastoma
  • brain cancer
  • cell signaling
  • tumor immunity
  • metabolic reprogramming
  • exosomes
  • receptor and ligand interaction
  • peptides
  • phage screening

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

19 pages, 1083 KiB  
Review
Overcoming Resistance to Temozolomide in Glioblastoma: A Scoping Review of Preclinical and Clinical Data
by Dimitra Smerdi, Myrto Moutafi, Ioannis Kotsantis, Lampis C. Stavrinou and Amanda Psyrri
Life 2024, 14(6), 673; https://doi.org/10.3390/life14060673 - 24 May 2024
Viewed by 91
Abstract
Glioblastoma (GB) is the most common and most aggressive primary brain tumor in adults, with an overall survival almost 14.6 months. Optimal resection followed by combined temozolomide chemotherapy and radiotherapy, also known as Stupp protocol, remains the standard of treatment; nevertheless, resistance to [...] Read more.
Glioblastoma (GB) is the most common and most aggressive primary brain tumor in adults, with an overall survival almost 14.6 months. Optimal resection followed by combined temozolomide chemotherapy and radiotherapy, also known as Stupp protocol, remains the standard of treatment; nevertheless, resistance to temozolomide, which can be obtained throughout many molecular pathways, is still an unsurpassed obstacle. Several factors influence the efficacy of temozolomide, including the involvement of other DNA repair systems, aberrant signaling pathways, autophagy, epigenetic modifications, microRNAs, and extracellular vesicle production. The blood–brain barrier, which serves as both a physical and biochemical obstacle, the tumor microenvironment’s pro-cancerogenic and immunosuppressive nature, and tumor-specific characteristics such as volume and antigen expression, are the subject of ongoing investigation. In this review, preclinical and clinical data about temozolomide resistance acquisition and possible ways to overcome chemoresistance, or to treat gliomas without restoration of chemosensitinity, are evaluated and presented. The objective is to offer a thorough examination of the clinically significant molecular mechanisms and their intricate interrelationships, with the aim of enhancing understanding to combat resistance to TMZ more effectively. Full article
(This article belongs to the Special Issue Evolving Chemotherapies in Glioblastomas(GBM)—Present and Future)
►▼ Show Figures

Figure 1

17 pages, 1787 KiB  
Review
Recent Advancements on the Use of Exosomes as Drug Carriers for the Treatment of Glioblastoma
by Angela Galardi, Alexander De Bethlen, Virginia Di Paolo, Silvia Lampis, Angela Mastronuzzi and Angela Di Giannatale
Life 2023, 13(4), 964; https://doi.org/10.3390/life13040964 - 7 Apr 2023
Cited by 4 | Viewed by 2277
Abstract
Glioblastoma (GBM) is the most common and aggressive cancer of the brain. Presently, GBM patients have a poor prognosis, and therapy primarily aims to extend the life expectancy of affected patients. The current treatment of GBM in adult cases and high-grade gliomas in [...] Read more.
Glioblastoma (GBM) is the most common and aggressive cancer of the brain. Presently, GBM patients have a poor prognosis, and therapy primarily aims to extend the life expectancy of affected patients. The current treatment of GBM in adult cases and high-grade gliomas in the pediatric population involves a multimodal approach that includes surgical resection followed by simultaneous chemo/radiotherapy. Exosomes are nanoparticles that transport proteins and nucleic acids and play a crucial role in mediating intercellular communication. Recent evidence suggests that these microvesicles may be used as biological carriers and offer significant advantages in targeted therapy. Due to their inherent cell-targeting properties, circulation stability, and biocompatibility, exosomes are emerging as promising new carriers for drugs and biotherapeutics. Furthermore, these nanovesicles are a repository of potential diagnostic and prognostic markers. In this review, we focus on the therapeutic potentials of exosomes in nano-delivery and describe the latest evidence of their use as a therapeutic tool in GBM. Full article
(This article belongs to the Special Issue Evolving Chemotherapies in Glioblastomas(GBM)—Present and Future)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop